Esperienza clinica con rivaroxaban nel trattamento del tromboembolismo venoso: Risultati dell'indagine epidemiologica italiana Survey TEV

Raffaele Pesavento, Ido Iori

Research output: Contribution to journalArticlepeer-review


Background. Rivaroxaban is a direct and selective inhibitor of factor Xa. The randomized clinical trials EINSTEIN evaluated the efficacy and safety of rivaroxaban for the treatment of venous thromboembolism (VTE) proving that the drug was non-inferior to standard treatment. The aim of this survey was to describe how rivaroxaban was used in a group of "real-life" patients with VTE. Methods. Between June and October 2014, physicians collected aggregate data, through an online questionnaire, on consecutive patients affected by VTE and treated with rivaroxaban in the previous 6 months. Descriptive statistics were performed on the collected data. Results. A total of 345 questionnaires were filled out. The mean age of patients was 62 years, with a low prevalence of concomitant diseases and/or pharmacological treatments. Deep vein thrombosis was diagnosed in 90% of patients and pulmonary embolism in 47%; only 48% was hospitalized. Rivaroxaban was prescribed at the recommended doses and/or regimen in no more than 60% of cases. In 96% of patients, the initial therapeutic plan did not require changes. Adherence to the therapeutic plan and overall patient satisfaction with therapy were high. Conclusions. Rivaroxaban was found easy to use and was highly appreciated by patients.

Original languageItalian
Pages (from-to)239-246
Number of pages8
JournalGiornale Italiano di Cardiologia
Issue number3
Publication statusPublished - Mar 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this